Developing an Oncolytic Prime-Boost Vaccine Targeting the Tumour Associated Antigen Mesothelin for the Treatment of Pancreatic Cancer
Pancreatic cancer (PDAC) affects 4400 Canadians each year and with 5year survival rates <8%, there is clearly an unmet need for new therapeutic approaches for treating this deadly disease. Herein I report the development of a surgical model of PDAC that recapitulates many of the hallmarks of huma...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
Université d'Ottawa / University of Ottawa
2020
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/40024 http://dx.doi.org/10.20381/ruor-24263 |